表观遗传错配修复缺陷与子宫内膜癌临床病理因素及生存在大规模多样化社区队列中的关联
该回顾性分析纳入6477例子宫内膜样癌患者,14.3%为表观遗传错配修复缺陷(MMRd)肿瘤。表观遗传MMRd与年龄≥70岁、肥胖、较高社会经济地位相关,在西班牙裔患者中较少见,与独立于肿瘤分级的非局限期分期相关,并在未接受辅助治疗的患者中与较低生存相关。
要点
- 6477例子宫内膜样癌中14.3%存在表观遗传MMRd。
- 表观遗传MMRd与年龄≥70岁、肥胖及较高社会经济地位相关,在西班牙裔患者中较少见。
- 未接受辅助治疗者中表观遗传MMRd与较低生存相关(HR 1.44),接受辅助治疗者中无此关联。
核心结论
- 在多样化社区队列中,表观遗传MMRd占子宫内膜样子宫内膜癌的14.3%,与年龄较大、肥胖和较高社会经济地位相关;控制这些因素后,表观遗传MMRd肿瘤在西班牙裔患者中较少见;表观遗传MMRd与独立于肿瘤分级的非局限期分期相关,并在未接受辅助治疗的患者中与较低生存相关。
研究设计与样本
- 回顾性分析纳入6477例子宫内膜样癌患者,肿瘤错配修复状态由通用筛查项目分类。
- 采用多变量回归评估表观遗传MMRd与种族、其他患者特征、肿瘤分级和分期的关联。
- 采用Kaplan-Meier法和Cox回归评估表观遗传MMRd与总生存的关联,并按是否接受辅助治疗分层。
主要发现
- 6477例患者中14.3%因表观遗传启动子高甲基化而存在MMRd肿瘤。
- 与错配修复功能正常(MMRp)肿瘤相比,表观遗传MMRd与年龄≥70岁(P < 0.001)和肥胖(P = 0.03)相关,但与吸烟或合并症负担无关。
- 表观遗传MMRd在西班牙裔患者中较少见(P < 0.01),在较低社会经济地位个体中也较少见(P < 0.001)。
- 表观遗传MMRd与独立于肿瘤分级的非局限期分期相关(aOR 1.28,95% CI 1.05-1.55,P = 0.01)。
- 在4754例(73%)未接受任何辅助治疗的患者中,表观遗传MMRd与较低生存相关(HR 1.44,95% CI 1.09-2.01,P = 0.02);在1723例(27%)接受辅助化疗、放疗和/或免疫治疗的患者中无此关联(HR 0.89,95% CI 0.60-1.33,P = 0.56)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate associations between epigenetic mismatch repair deficiency (MMRd), clinicopathologic factors and overall survival in a diverse endometrial cancer cohort. METHODS: Retrospective analysis of patients with endometrioid cancer whose tumor mismatch repair status was classified by a universal screening program. Associations between epigenetic MMRd, race, other patient characteristics, tumor grade, and stage were assessed using multivariate regression. The Kaplan-Meier method and Cox regression were used to evaluate the association between epigenetic MMRd and overall survival, stratified by receipt of adjuvant therapy. RESULTS: Among 6477 patients, 14.3 % were found to have MMRd tumors due to epigenetic promoter hypermethylation. Compared to MMR proficient (MMRp) tumors, epigenetic MMRd was associated with age ≥ 70 (P < 0.001) and obesity (P = 0.03) but not smoking or comorbidity burden and were less common in Hispanic patients (P < 0.01) and individuals of lower socioeconomic status (P < 0.001). Epigenetic MMRd was associated with non-localized stage independent of tumor grade (aOR 1.28, 95 % CI 1.05-1.55, P = 0.01) and lower survival among the 4754 (73 %) patients not treated with any adjuvant therapy (HR 1.44, 95 % CI 1.09-2.01, P = 0.02) but not among 1723 (27 %) who received adjuvant chemotherapy, radiotherapy and/or immunotherapy (HR 0.89, 95 % CI 0.60-1.33, P = 0.56). CONCLUSION: In a diverse community-based cohort, epigenetic MMRd characterized 14.3 % of endometrioid endometrial cancers and was associated with older age, obesity, and higher socioeconomic status. Controlling for these factors, epigenetic MMRd tumors were less common among Hispanic patients. Epigenetic MMRd was associated with non-localized stage independent of tumor grade and lower survival among patients who did not receive adjuvant therapy.
引用
- Suh-Burgmann E, Hung YY, Finertie H, et al. Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort. Gynecol Oncol. 2025. PMID: 40327909. doi:10.1016/j.ygyno.2025.04.584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。